A Smart Detection System Based on Specific Magnetic and Rolling Cycle Amplification Signal-Amplified Dual-Aptamers to Accurately Monitor Minimal Residual Diseases in Patients with T-ALL

A Smart Detection System Based on Specific Magnetic and Rolling Cycle Amplification Signal-Amplified Dual-Aptamers to Accurately Monitor Minimal Residual Diseases in Patients with T-ALL
复制标题

基于特异性磁和滚动循环放大信号放大双适配体的智能检测系统,准确监测T-ALL患者的微小残留疾病

DOI:
10.1166/jbn.2016.2302
复制
发表时间:
2016
影响因子:
2.9
通讯作者:
Yongxiang Zhao
Yongxiang Zhao
中科院分区:
工程技术3区
文献类型:
--
作者:
Xia Li;Bo Zhou;Zilong Zhao;Zixi Hu;Sufang Zhou;Nuo Yang;Yong Huang;Zhenghua Zhang;Jing Su;Dan Lan;Xue Qin;Jinyu Meng;Duo Zheng;Jian He;Xianing Huang;Jing Zhao;Zhiyong Zhang;Weihong Tan;Xiaoling Lu;Yongxiang Zhao

文献摘要

相似文献

如何早期发现白血病微小残留病是临床上面临的一大挑战。在这里,我们开发了一种用于MRD的智能检测系统,该系统涉及磁性适体sgc 8探针(M-sgc 8 probe)以捕获CEM细胞和滚动循环扩增探针(RCA-sgc 8 probe)以启动RCA,产生环状模板的单链串联重复拷贝。DNA产物与分子信标杂交产生放大的荧光信号。建立了模拟MRD的体外模型,以评估智能检测系统的灵敏度。将该智能检测系统应用于T-ALL患者化疗期间的MRD检测,不仅可以特异性捕获T-ALL细胞,而且可以显著放大其上的荧光信号。灵敏度为1/20,000。这些结果表明,具有高特异性和灵敏度的智能检测系统可以更有效地监测T-ALL化疗期间的进展。
It is a major clinical challenge for clinicians how to early find out minimal residual diseases (MRD) of leukemia. Here, we developed a smart detection system for MRD involving magnetic aptamer sgc8 probe (M-sgc8 probe) to capture CEM cells and rolling cycle amplification probe (RCA-sgc8 probe) to initiate RCA, producing a single-stranded tandem repeated copy of the circular template. The DNA products were hybridized with molecular beacon to generate the amplified fluorescence signal. An in vitro model to mimic MRD was established to evaluate the sensitivity of the smart detection system. The smart detection system was used to detect MRD in patients with T-ALL peri-chemotherapy, which could not only specifically captured T-ALL cells, but also significantly amplified fluorescence signals on them. The sensitivity was 1/20,000. These results indicate that the smart detection system with high specificity and sensitivity could more efficiently monitor the progress of T-ALL peri-chemotherapy.